| Small Animal Platform |
|
|
|
Animal Facility![]() Located in the Jean Roget Institute the experimental animal platform covers 1350m2 of floor space. It is divided into 5 areas maintained under pressurized conditions for the housing of up to 15,000 transgenic and immuno-deficient animals in an SPF (specific pathogen free) environment. A2 and A3 laboratories are available.
Services Available
• Rearing, management and development of rodent lines bred for experiments and distribution to external laboratories and for use in training in an SPOF (specific opportunist pathogen free) and conventional environment. Housing and experimentation in microbiological confinement to levels A1 to A3. Manipulation of products requiring specific levels of confinement (pathogens, molecules of unknown incidence, nanoparticles)• Decontamination and revival of animal lines by embryo transfer • Genotyping for the genetic characterisation and analysis of lines; • Cell reimplantation service by ES (embryonic stem cell) injection into blastocytes or cell aggregation Immunization service for antibody production (monoclonal and polyclonal) • Injections of antigens • Serum samples taken for tests carried out at laboratory level • Animal imaging services (proposed future development to place rodents in-house in imaging platform) • Experiments carried out by qualified technicians of the platform (with the potential to transfer know-how to the relevant laboratories) • Expertise acquired in animal experimentation (list of competencies available on request) At outsourcing and consultancy level ![]() • Embryo freezing/ storing • Consulting services for laboratories concerning analyses that need to be carried out on their animal lines • Expert advice on breeding strategies for animals destined for experiments and for associated experimentation techniques Contacts Marie-Gabrielle Jouan +33 (0)4 76 00 00 61 This e-mail address is being protected from spambots. You need JavaScript enabled to view it ![]() |
| "Thanks to the Optical Imaging Platform we have been able to carry out preliminary trials" JS Sun, DNA Therapeutics |
| Read more... |